DK120091A - Tripelstrenget nukleinsyre og anvendelse heraf - Google Patents
Tripelstrenget nukleinsyre og anvendelse heraf Download PDFInfo
- Publication number
- DK120091A DK120091A DK120091A DK120091A DK120091A DK 120091 A DK120091 A DK 120091A DK 120091 A DK120091 A DK 120091A DK 120091 A DK120091 A DK 120091A DK 120091 A DK120091 A DK 120091A
- Authority
- DK
- Denmark
- Prior art keywords
- synthetic oligonucleotides
- dna
- bind
- duplex
- target sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01034—Hydroxymethylglutaryl-CoA reductase (NADPH) (1.1.1.34)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01018—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28735988A | 1988-12-20 | 1988-12-20 | |
PCT/US1989/005769 WO1990006934A1 (en) | 1988-12-20 | 1989-12-20 | Triple stranded nucleic acid and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
DK120091A true DK120091A (da) | 1991-06-20 |
DK120091D0 DK120091D0 (da) | 1991-06-20 |
Family
ID=23102554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK911200A DK120091D0 (da) | 1988-12-20 | 1991-06-20 | Tripelstrenget nukleinsyre og anvendelse heraf |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0375408B1 (da) |
JP (1) | JPH04502407A (da) |
AT (1) | ATE118818T1 (da) |
AU (1) | AU640910B2 (da) |
CA (1) | CA2006008C (da) |
DE (1) | DE68921315T2 (da) |
DK (1) | DK120091D0 (da) |
ES (1) | ES2069598T3 (da) |
PT (1) | PT92640B (da) |
WO (1) | WO1990006934A1 (da) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5928863A (en) * | 1986-11-26 | 1999-07-27 | Princeton University | Triple-stranded nucleic acids |
US5422251A (en) * | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
US5849482A (en) * | 1988-09-28 | 1998-12-15 | Epoch Pharmaceuticals, Inc. | Crosslinking oligonucleotides |
US5399676A (en) * | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5721218A (en) * | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
IE911115A1 (en) * | 1990-04-10 | 1991-10-23 | Canji Inc | Gene therapy for cell proliferative diseases |
CA2083719A1 (en) * | 1990-05-25 | 1991-11-26 | Mark D. Matteucci | "sequence-specific non-photoactivated crosslinking agents which bind to the major groove of duplex dna |
EP0463712A3 (en) * | 1990-06-27 | 1992-04-08 | University Patents, Inc. | Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections |
US5734022A (en) * | 1990-08-01 | 1998-03-31 | The Johns Hopkins University | Antibodies to a novel mammalian protein associated with uncontrolled cell division |
WO1992009705A1 (en) * | 1990-11-23 | 1992-06-11 | Gilead Sciences, Inc. | Triplex-forming oligomers containing modified bases |
WO1992011390A1 (en) * | 1990-12-17 | 1992-07-09 | Idexx Laboratories, Inc. | Nucleic acid sequence detection by triple helix formation |
US5683874A (en) * | 1991-03-27 | 1997-11-04 | Research Corporation Technologies, Inc. | Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence |
US6136601A (en) * | 1991-08-21 | 2000-10-24 | Epoch Pharmaceuticals, Inc. | Targeted mutagenesis in living cells using modified oligonucleotides |
JPH06510203A (ja) * | 1991-08-30 | 1994-11-17 | ザ・ジョーンズ・ホプキンス・ユニバーシティ | プリン塩基類似体を含むヌクレオシドオリゴマーを用いる二重鎖dnaの三重らせん複合体の形成 |
IL103311A0 (en) * | 1991-10-07 | 1993-03-15 | Univ Johns Hopkins | Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers |
US5594121A (en) * | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
WO1993009127A1 (en) * | 1991-11-07 | 1993-05-13 | Gilead Sciences, Inc. | Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs |
US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
TW393513B (en) * | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
EP1256589A3 (en) * | 1991-11-26 | 2003-09-17 | Isis Pharmaceuticals, Inc. | Oligomers containing modified pyrimidines |
US5484908A (en) * | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5616461A (en) * | 1992-05-14 | 1997-04-01 | Dana-Farber Cancer Institute | Assay for antiviral activity using complex of herpesvirus origin of replication and cellular protein |
US6403302B1 (en) | 1992-09-17 | 2002-06-11 | California Institute Of Technology | Methods and compositions for triple helix formation |
WO1994007367A1 (en) * | 1992-09-29 | 1994-04-14 | Apollon, Inc. | Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids |
CA2148687A1 (en) * | 1992-11-09 | 1994-05-26 | Darwin Prockop | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
EP0674707A4 (en) * | 1992-12-04 | 1998-01-14 | Apollon Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF LEUCOMA. |
EP0673260A4 (en) * | 1992-12-08 | 1999-04-14 | Genta Inc | FORMATION OF TRIPLE PROPELLER COMPLEXES USING A NEW PATTERN. |
WO1994017092A1 (en) * | 1993-01-26 | 1994-08-04 | Microprobe Corporation | Bifunctional crosslinking oligonucleotides adapted for linking to a desired gene sequence of invading organism or cell |
US6288042B1 (en) | 1993-04-23 | 2001-09-11 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich tetrad forming oligonucleotides |
US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
US6323185B1 (en) | 1993-04-23 | 2001-11-27 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-viral guanosine-rich oligonucleotides and method of treating HIV |
WO1995000638A2 (en) * | 1993-06-23 | 1995-01-05 | Genesys Pharma Inc. | Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection |
AU691194B2 (en) * | 1993-06-25 | 1998-05-14 | Yale University | Chemically modified oligonucleotide for site-directed mutagenesis |
US5962426A (en) | 1993-06-25 | 1999-10-05 | Yale University | Triple-helix forming oligonucleotides for targeted mutagenesis |
EP1683863A3 (en) * | 1993-10-18 | 2006-08-02 | The Walter And Eliza Hall Institute Of Medical Research | A method for enhancing neurone survival and agents useful for same |
US5602109A (en) * | 1994-01-10 | 1997-02-11 | Abbott Laboratories | Method to enhance the immune system of a human |
US5488039A (en) * | 1994-01-10 | 1996-01-30 | Abbott Laboratories | Method for the production of an enteral formula containing ribo-nucleotides |
US5700590A (en) * | 1994-01-10 | 1997-12-23 | Abbott Laboratories | Nutritional formula with ribo-nucleotides |
US6136858A (en) | 1994-01-10 | 2000-10-24 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
US5492899A (en) * | 1994-01-10 | 1996-02-20 | Abbott Laboratories | Infant nutritional formula with ribo-nucleotides |
US5808037A (en) * | 1995-09-15 | 1998-09-15 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
US5780611A (en) * | 1995-09-15 | 1998-07-14 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
US6156513A (en) * | 1995-09-15 | 2000-12-05 | Ramareddy V. Guntaka | Oligmers which inhibit expression of collagen genes |
FR2746412B1 (fr) | 1996-03-21 | 1998-06-12 | Rhone Poulenc Rorer Sa | Purification d'adn plasmidique de qualite pharmaceutique |
US6312925B1 (en) | 1997-05-08 | 2001-11-06 | Epoch Pharmaceuticals, Inc. | Methods and compositions to facilitate D-loop formation by oligonucleotides |
US6930175B1 (en) | 1997-12-12 | 2005-08-16 | The Johns Hopkins University School Of Medicine | Gene family with transformation modulating activity |
US7314926B1 (en) * | 1999-04-08 | 2008-01-01 | Antisoma Research Limited | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin |
US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
FR2822156A1 (fr) * | 2001-03-16 | 2002-09-20 | Centre Nat Rech Scient | Oligonucleotides pour la regulation du gene codant pour le tnf alpha et/ou de genes sous son controle et leurs applications |
US8129514B2 (en) | 2003-06-19 | 2012-03-06 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
US7498428B2 (en) | 2003-06-19 | 2009-03-03 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
CN101273130B (zh) | 2005-07-07 | 2012-05-30 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 用于下调h19的核酸物质及其使用方法 |
US8658608B2 (en) | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
EP2111450A2 (en) | 2007-01-16 | 2009-10-28 | Yissum Research Development Company of the Hebrew University of Jerusalem | Nucleic acid constructs and methods for specific silencing of h19 |
WO2009010968A2 (en) | 2007-07-15 | 2009-01-22 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
AU2008299784B9 (en) | 2007-08-02 | 2015-06-18 | Gilead Biologics, Inc. | LOX and LOXL2 inhibitors and uses thereof |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
ES2633786T3 (es) | 2008-04-01 | 2017-09-25 | Biosearch Technologies, Inc. | Sondas de fluoróforo atenuadoras oscuras de ácido nucleico estabilizado |
AU2009298802A1 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
DK2414542T3 (da) | 2009-03-30 | 2017-11-27 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose |
CA2770276A1 (en) | 2009-08-21 | 2012-02-24 | Beeologics, Inc. | Preventing and curing beneficial insect diseases via plant transcribed molecules |
RU2012110585A (ru) | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | Каталичические домены лизилоксидазы и loxl2 |
US9610331B2 (en) | 2009-09-08 | 2017-04-04 | Yeda Research And Development Co. Ltd. | Methods for hematopoietic precursor mobilization |
US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
CN105368836A (zh) | 2009-10-14 | 2016-03-02 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 用于控制蜂中的瓦螨的组合物 |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
AU2011212830B2 (en) | 2010-02-04 | 2014-05-22 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor |
WO2011132182A1 (en) | 2010-04-18 | 2011-10-27 | Yeda Research And Development Co. Ltd. | MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES |
US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
WO2011133876A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
WO2011158243A2 (en) | 2010-06-16 | 2011-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of diagnosing and treating cancer |
WO2012035539A1 (en) | 2010-09-15 | 2012-03-22 | Ramot At Tel-Aviv University Ltd. | Methods of expanding and redifferentiating islet beta cells |
EP2627766B1 (en) | 2010-10-17 | 2016-05-25 | Yeda Research and Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
US9415103B2 (en) | 2011-06-14 | 2016-08-16 | Yeda Research And Development Co. Ltd. | Combination therapy to prevent DCIS formation and progression to breast cancer |
EP2741753A2 (en) | 2011-08-09 | 2014-06-18 | Yeda Research and Development Co. Ltd. | Downregulation of mir-7 for promotion of beta cell differentiation and insulin production |
EP2771464B1 (en) | 2011-10-27 | 2018-03-21 | Yeda Research and Development Co. Ltd. | Methods of treating cancer |
WO2013076730A1 (en) | 2011-11-27 | 2013-05-30 | Yeda Research And Development Co. Ltd. | Methods of regulating angiogenesis and compositions capable of same |
WO2013124816A2 (en) | 2012-02-22 | 2013-08-29 | Brainstem Biotec Ltd. | Generation of neural stem cells and motor neurons |
BR112015026702A2 (pt) | 2013-04-21 | 2018-02-06 | Yeda Res And Developmente Co Ltd | métodos de extermínio de células senescentes |
CA2918387C (en) | 2013-07-19 | 2021-11-02 | Monsanto Technology Llc | Compositions and methods for controlling leptinotarsa |
NZ719544A (en) | 2013-11-04 | 2022-09-30 | Beeologics Inc | Compositions and methods for controlling arthropod parasite and pest infestations |
CN106470699A (zh) | 2014-02-03 | 2017-03-01 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 使用酪蛋白激酶i抑制剂以消耗干细胞的用途 |
EP3420809A1 (en) | 2014-04-01 | 2019-01-02 | Monsanto Technology LLC | Compositions and methods for controlling insect pests |
WO2016018887A1 (en) | 2014-07-29 | 2016-02-04 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
CN108064274A (zh) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | 用于培养多能干细胞的培养基 |
WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
EP3220945A2 (en) | 2014-11-17 | 2017-09-27 | Yeda Research and Development Co., Ltd. | Methods of treating diseases related to mitochondrial function |
US10968449B2 (en) | 2015-01-22 | 2021-04-06 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
WO2016135732A1 (en) | 2015-02-26 | 2016-09-01 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
WO2016135716A1 (en) | 2015-02-26 | 2016-09-01 | Jacob Schneiderman | Methods and compositions relating to leptin antagonists |
US10907152B2 (en) | 2015-05-04 | 2021-02-02 | Monsanto Technology Llc | Compositions and methods for controlling arthropod parasite and pest infestations |
WO2016181393A1 (en) | 2015-05-11 | 2016-11-17 | Yeda Research And Development Co. Ltd. | Citrin inhibitors for the treatment of cancer |
WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
EP3297727A1 (en) | 2015-05-21 | 2018-03-28 | Yeda Research and Development Co. Ltd | Bacterial populations for promoting health |
AU2016295168B2 (en) | 2015-07-17 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
US20180221393A1 (en) | 2015-08-03 | 2018-08-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
WO2017081686A1 (en) | 2015-11-10 | 2017-05-18 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Means and methods for reducing tumorigenicity of cancer stem cells |
JP2019505511A (ja) | 2016-01-06 | 2019-02-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 |
AU2017221405A1 (en) | 2016-02-16 | 2018-09-20 | Carnegie Mellon University | Compositions for enhancing targeted gene editing and methods of use thereof |
US20190216891A1 (en) | 2016-03-06 | 2019-07-18 | Yeda Research And Development Co., Ltd. | Method for modulating myelination |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
WO2019021289A1 (en) | 2017-07-27 | 2019-01-31 | The National Institute for Biotechnology in the Negev Ltd. | SMAC / DIABLO INHIBITORS USEFUL IN THE TREATMENT OF CANCER |
IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
EP3723785A1 (en) | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Cop9 signalosome (csn) complex modulators and uses thereof |
EP3749368A1 (en) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
EP3773506A4 (en) | 2018-03-29 | 2021-12-22 | Technion Research & Development Foundation Limited | VESICLES INCLUDING A PTEN INHIBITOR AND THEIR USES |
KR20210018267A (ko) | 2018-05-07 | 2021-02-17 | 알닐람 파마슈티칼스 인코포레이티드 | 간외 전달 |
EP3927378A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
JP2022532652A (ja) | 2019-05-17 | 2022-07-15 | アルニラム ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの経口送達 |
WO2021019526A1 (en) | 2019-07-29 | 2021-02-04 | Yeda Research And Development Co. Ltd. | Methods of treating and diagnosing lung cancer |
WO2022011214A1 (en) | 2020-07-10 | 2022-01-13 | Alnylam Pharmaceuticals, Inc. | Circular sirnas |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2023018621A1 (en) | 2021-08-10 | 2023-02-16 | Gamida-Cell Ltd. | Engineered nk cells, methods of their production and uses thereof |
WO2023220744A2 (en) | 2022-05-13 | 2023-11-16 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
-
1989
- 1989-12-19 CA CA002006008A patent/CA2006008C/en not_active Expired - Fee Related
- 1989-12-20 PT PT92640A patent/PT92640B/pt not_active IP Right Cessation
- 1989-12-20 EP EP89313391A patent/EP0375408B1/en not_active Expired - Lifetime
- 1989-12-20 EP EP19900901460 patent/EP0449972A4/en active Pending
- 1989-12-20 WO PCT/US1989/005769 patent/WO1990006934A1/en not_active Application Discontinuation
- 1989-12-20 DE DE68921315T patent/DE68921315T2/de not_active Expired - Fee Related
- 1989-12-20 ES ES89313391T patent/ES2069598T3/es not_active Expired - Lifetime
- 1989-12-20 JP JP2502252A patent/JPH04502407A/ja active Pending
- 1989-12-20 AT AT89313391T patent/ATE118818T1/de not_active IP Right Cessation
- 1989-12-20 AU AU48384/90A patent/AU640910B2/en not_active Ceased
-
1991
- 1991-06-20 DK DK911200A patent/DK120091D0/da not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ATE118818T1 (de) | 1995-03-15 |
AU4838490A (en) | 1990-07-10 |
CA2006008C (en) | 2000-02-15 |
EP0375408A1 (en) | 1990-06-27 |
EP0375408B1 (en) | 1995-02-22 |
JPH04502407A (ja) | 1992-05-07 |
WO1990006934A1 (en) | 1990-06-28 |
DE68921315T2 (de) | 1995-08-03 |
DE68921315D1 (de) | 1995-03-30 |
PT92640A (pt) | 1990-06-29 |
EP0449972A1 (en) | 1991-10-09 |
CA2006008A1 (en) | 1990-06-20 |
AU640910B2 (en) | 1993-09-09 |
DK120091D0 (da) | 1991-06-20 |
PT92640B (pt) | 1995-09-12 |
EP0449972A4 (en) | 1992-03-18 |
ES2069598T3 (es) | 1995-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK120091A (da) | Tripelstrenget nukleinsyre og anvendelse heraf | |
DE69627698D1 (de) | Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren | |
EP0828849A4 (en) | OLIGONUCLEOTIDE LIGANDS WITH HIGH AFFINITY FOR GROWTH FACTORS | |
ATE239090T1 (de) | Methode zum generieren von einzelsträngigen dna molekülen | |
US5403708A (en) | Methods and compositions for determining the sequence of nucleic acids | |
DK51092D0 (da) | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf | |
DE3850093T2 (de) | Verfahren zur Amplifizierung von Nukleinsäuren. | |
AU3728093A (en) | Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids | |
FI102387B1 (fi) | Menetelmä ribonukleiinihapon (RNA) valmistamiseksi | |
EP0331939A3 (en) | Method and compositions for conferring resistance to retroviral infection | |
FI893526A (fi) | Material och metod foer oekning av nukleinsyrahybridisering. | |
EP0285123A3 (en) | A method for complete mutagenesis of nucleic acids | |
EP0369360A3 (en) | Differentiation of nucleic acid segments on the basis of nucleotide differences | |
DE69133629D1 (de) | nssystem zur Bestimmung von genetischen Krankheiten | |
Slettan et al. | Isolation and characterization of variable (GT) n repetitive sequences from Atlantic salmon, Salmo salar L. | |
Collick et al. | Minisatellite binding protein Msbp-1 is a sequence-specific single-stranded DNA-binding protein | |
ATE317123T1 (de) | Reaktiver träger zur bestimmung von dna fragmenten | |
DE69626032D1 (de) | Modifizierung von oligonukleotid-primer-sequenzen zum manipilieren der zugabe von nicht-template-nukleotiden | |
Sá-Carvalho et al. | Sequences with high propensity to form G-quartet structures in kinetoplast DNA from Phytomonas serpens | |
HK74595A (en) | Specific nucleic-acid fragments of the human villin gene and their application to diagnostic ends | |
Holden | Map marks the X (chromosome) | |
James Shen | Superhetieity induces hypersensitivity of a human polypyrimldine polypurine DNA sequence in the human α2-α1 globin intergenic region to SI nudease digestion-high resolution mapping of the clustered cleavage sites | |
Austerberry | DEVELOPMENTALLY REGULATED DNA DELETION IN TETRAHYMENA THERMOPHILA. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AHS | Application shelved for other reasons than non-payment |